Skip to main content
Skip to main content
APYP logo

AppYea, Inc. (APYP) Stock Analysis

Educational signal · not a buy or sell recommendation · How to read this

DELISTED

What happened to AppYea, Inc. (APYP) stock?

AppYea, Inc. (APYP) no longer trades on public markets. The figures below are historical and are not a current quote.

MCap: $5.15M| Vol: 5.5K| 52-wk range: $0.0057 – $0.0346

Market cap $5.15M is the value of all shares combined. Beta 0.11: the stock has moved about 89% less than the S&P 500.

Data from FMP · Methodology

For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR

AppYea, Inc. (APYP). AppYea, Inc. is a digital health company specializing in sensor monitoring and software solutions for snoring and sleep apnea. Market cap: $5.15M, Sector: Technology.

Last analyzed: Mar 15, 2026
AppYea, Inc. is a digital health company specializing in sensor monitoring and software solutions for snoring and sleep apnea. Their product line includes smartphone applications and wristbands designed to detect and treat sleep-related breathing disorders.

Analyst Coverage for APYP: APYP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates APYP against Technology peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.

Watch the APYP film Every key number, told as a short cinematic story — just press play. ~2 min

These figures come from statements filed 12 months ago — the most recent this company has published.

Council Score · Weighted Average of 3 Disciplines
Split View 38/100 · D

APYP: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.

How is this calculated? →
Legends Council · 5 Legends + Moon AI

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated)Ray Dalio
Favorable read
Griffin-style lens (simulated)Ken Griffin
Unfavorable read
Simons-style lens (simulated)Jim Simons
Neutral read
Englander-style lens (simulated)Izzy Englander
Neutral read
Klarman-style lens (simulated)Seth Klarman
Unfavorable read
Moon AI lens (model)
Unfavorable read
Munger's Mindset · Balance Sheet & Valuation
Financial Health
Weak
Margin of Safety
Fairly Valued
Council Score · Weighted Average of 3 Disciplines · See tabs for details →
The lenses are modelled on the published principles of the investors named. We are not affiliated with them, they have not endorsed this, and it is not their opinion of this stock.

AppYea, Inc. (APYP) Technology Profile & Competitive Position

CEOYakir Abady
Employees3
HeadquartersGan Yavne, IL
IPO Year2014

AppYea, Inc. develops and patents digital health solutions for sleep apnea and snoring, focusing on sensor-based monitoring and real-time detection. Their SleepX app and DreamIT wristband aim to provide accessible and convenient sleep disorder management, positioning them in the growing market for digital health technologies.

Data Provenance | Financial Data Quantitative Analysis Analysis: Mar 15, 2026

What Is the Investment Thesis for APYP?

AI-written as of Mar 15, 2026 — figures and tone reflect the data available then, not today's score.

AppYea, Inc. presents a focused investment opportunity within the digital health sector, specifically targeting the sleep apnea and snoring market. With a market capitalization of $5.15M and a gross margin of 15.8%, the company is positioned to capitalize on the increasing demand for accessible and convenient sleep monitoring and treatment solutions. Key value drivers include the continued development and refinement of their SleepX and DreamIT product lines, expansion into new markets, and potential partnerships with healthcare providers. The company's low beta of 0.11 suggests relatively low volatility compared to the broader market. However, investors should be aware of the risks associated with investing in OTC-listed companies and the competitive landscape of the digital health market.

Based on FMP financials and quantitative analysis

APYP Key Highlights

AI-written as of Mar 15, 2026 — figures and tone reflect the data available then, not today's score.

Market capitalization of $5.15M, reflecting its current valuation in the OTC market.

  • Gross margin of 15.8%, indicating the profitability of its products before operating expenses.
  • Free cash flow of $-0.00B, highlighting the need for careful cash management and potential future financing.
  • Beta of 0.11, suggesting lower volatility compared to the overall market.
  • Focus on the digital health market for sleep apnea and snoring, addressing a significant and growing health concern.

Who Are APYP's Competitors?

APYP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap MoonshotScore
MNDO MIND C.T.I. Ltd. $1.02 +3.00% $20.9M 795-pillar
IDN Intellicheck, Inc. $2.62 +0.77% $53.1M 765-pillar
WFCF Where Food Comes From, Inc. $13.20 +3.94% $66.5M 725-pillar
TRAK ReposiTrak, Inc. $7.89 +0.25% $143M 785-pillar
PERF Perfect Corp. $1.93 +0.52% $197M 865-pillar
IMMR Immersion Corporation $7.36 -1.08% $244M 785-pillar
RMNI Rimini Street, Inc. $4.58 +0.11% $427M 775-pillar
MTLS Materialise NV $7.64 +2.83% $447M 755-pillar

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are APYP's Key Strengths?

Proprietary technology for sleep monitoring and treatment.

  • Integrated solution combining app and wearable device.
  • Focus on the growing market for digital health solutions.
  • Low beta indicating lower volatility.

What Are APYP's Weaknesses?

Limited financial resources.

  • Small number of employees.
  • Dependence on single product line.
  • OTC listing presents liquidity and regulatory challenges.

What Could Drive APYP Stock Higher?

Potential partnerships with healthcare providers and sleep clinics.

  • Continued development and refinement of SleepX and DreamIT product lines.
  • Expansion into new geographic markets.
  • Increased adoption of telehealth and remote patient monitoring.

What Are the Key Risks for APYP?

Financial-distress signal — its Altman Z-Score of -5.74 sits in the distress zone (elevated bankruptcy risk).

  • Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
  • Competition from established medical device companies.
  • Technological obsolescence.
  • Limited financial resources.
  • OTC listing presents liquidity and regulatory challenges.
  • Regulatory changes in the healthcare industry.

What Are the Growth Opportunities for APYP?

  • Expansion into New Markets: AppYea can expand its market reach beyond its current base by targeting new geographic regions and demographic segments. Timeline: Ongoing.
  • Strategic Partnerships: Collaborating with healthcare providers, sleep clinics, and insurance companies can accelerate adoption of AppYea's solutions and increase market penetration. Partnerships can provide access to established distribution channels and patient networks. Timeline: Ongoing.
  • Product Innovation: Continuous innovation and development of new features for the SleepX and DreamIT product lines can enhance their value proposition and attract new customers. This includes incorporating advanced sensor technologies, AI-powered analytics, and personalized treatment plans. Timeline: Ongoing.
  • Direct-to-Consumer Marketing: Implementing targeted marketing campaigns to reach consumers directly through online channels, social media, and digital advertising can increase brand awareness and drive sales. This approach allows AppYea to bypass traditional healthcare channels and reach a wider audience. Timeline: Ongoing.
  • Integration with Telehealth Platforms: Integrating AppYea's solutions with telehealth platforms can provide remote monitoring and treatment options for patients with sleep apnea and snoring. This integration can enhance patient engagement and improve treatment outcomes. Timeline: Ongoing.

What Are APYP's Competitive Advantages?

  • Proprietary Algorithms: Unique algorithms for monitoring breathing and detecting snoring/sleep apnea events.
  • Patented Technology: Designs and patents for sensor monitoring and software solutions.
  • Integrated Solution: Combination of smartphone application and wearable device for comprehensive sleep monitoring and treatment.

What Does APYP Do?

Founded in 2012 and based in Rehovot, Israel, AppYea, Inc. operates as a digital health company focused on designing, patenting, and producing sensor monitoring and software solutions for snoring and sleep apnea. The company's core product offerings include the SleepX App and DreamIT wristband. The SleepX App is a smartphone application that employs unique algorithms to monitor breathing and detect snoring events in real time. Complementing the app, the DreamIT wristband features various sensors and interfaces with the SleepX App to provide treatment for snoring. AppYea also offers SleepX PRO, an application designed to monitor breathing and detect sleep apnea incidents, and DreamIT PRO, a wristband that interfaces with the SleepX PRO app for sleep apnea treatment. AppYea aims to provide accessible and convenient solutions for individuals suffering from sleep-related breathing disorders, leveraging technology to improve sleep quality and overall health.

What Products and Services Does APYP Offer?

  • Designs and patents sensor monitoring solutions.
  • Develops software for snoring and sleep apnea detection.
  • Produces the SleepX App for real-time snoring monitoring.
  • Manufactures the DreamIT wristband for snoring treatment.
  • Offers SleepX PRO for sleep apnea detection.
  • Provides DreamIT PRO for sleep apnea treatment.

How Does APYP Make Money?

  • Develops and sells sensor-based monitoring devices (DreamIT wristband).
  • Offers smartphone applications (SleepX App, SleepX PRO) for sleep monitoring and treatment.
  • Generates revenue through direct sales to consumers.
  • Potential for future revenue through partnerships with healthcare providers and insurance companies.

What Industry Does APYP Operate In?

AppYea, Inc. operates within the rapidly expanding digital health market, specifically targeting sleep apnea and snoring solutions. The industry is characterized by increasing adoption of telehealth and remote patient monitoring technologies. The competitive landscape includes established medical device companies, as well as emerging digital health startups. AppYea's focus on sensor-based monitoring and smartphone integration positions it to capitalize on the growing demand for accessible and convenient sleep disorder management.

Who Are APYP's Key Customers?

  • Individuals suffering from snoring.
  • Individuals suffering from sleep apnea.
  • Healthcare providers seeking remote patient monitoring solutions.
  • Sleep clinics and sleep disorder centers.
Model self-rating on this text: 66% (not a measure of the evidence) Updated: Mar 15, 2026

Research confidence

Low 37/100

Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.

  • Scoring coverage unknown
  • Price 5 days old
  • Latest filing 28 days ago
  • No analyst coverage

MoonshotScore History

Recorded daily since 2026-08-23 · 4 snapshots

2026-08-23 50
2026-08-24 50
2026-08-25 50
2026-08-26 50

What changed?

The score has stayed at 50.

Over the same 3 days the stock moved +11.2%.

Company Profile

AppYea, Inc. operates in the Information Technology Services industry within the Technology sector. It is headquartered in Gan Yavne, IL. The company is led by CEO Yakir Abadi. APYP has traded publicly since 2014.

Key Financial Metrics

Return on assets is -76.6%, showing how much profit it generates from its asset base. Its free cash flow yield is -17.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.10 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -190.9%, the inverse of the P/E and a quick read on earnings relative to price.

APYP Valuation & Market Position

With a $5.15M market cap, AppYea, Inc. sits in the micro-cap segment of the market.

Quarterly Financial Performance: AppYea, Inc.

Revenue for AppYea, Inc. came in at $0 during Q2 FY2026. The company recorded a net loss of $1.9M, with diluted EPS of $-0.00. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Technology. Across the four most recent quarters, APYP averaged $-0.01 in diluted EPS.

F-Score 3/9

Financial Health

AppYea, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -5.74 places it in the distress zone, a signal of elevated financial risk.

Net selling

Insider Activity

The most recent 11 insider filings for AppYea, Inc. break down as 10 sales and 1 purchases. On net that is roughly 499.0M shares disposed (about $115K), a signal worth weighing alongside the fundamentals.

APYP Financials

Fundamental Snapshot

Revenue Growth (FY)
-72.4%
Net Income Growth (FY)
-274.4%
EPS Growth (FY)
-192.0%
Free Cash Flow Growth (FY)
+29.9%
Current Ratio
0.1

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Proprietary technology for sleep monitoring and treatment.
  • Integrated solution combining app and wearable device.
  • Focus on the growing market for digital health solutions.
  • Low beta indicating lower volatility.

Bear Case

  • Limited financial resources.
  • Small number of employees.
  • Dependence on single product line.
  • OTC listing presents liquidity and regulatory challenges.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

Recent Quarterly Results

Quarter Revenue Net Income EPS
Q2 FY2026 $0 -$2M -$0.0021
Q1 FY2026 $0 -$2M -$0.0018
Q4 FY2025 $2,000 -$10M -$0.02
Q3 FY2025 $2,000 -$5M -$0.01

Q2 FY2026 · filed 14 Aug 2026 · SEC EDGAR →

Based on FMP financials and quantitative analysis

APYP Latest News

Leadership: Yakir Abady

CEO

Yakir Abady serves as the CEO of AppYea, Inc. His background includes experience in managing and leading technology-driven companies. He is responsible for overseeing the company's strategic direction, product development, and overall operations. His leadership is focused on driving innovation and growth in the digital health market, particularly in the area of sleep apnea and snoring solutions.

Track Record: Under Yakir Abady's leadership, AppYea, Inc. has focused on developing and commercializing its SleepX and DreamIT product lines. Key milestones include securing patents for its sensor monitoring technology and expanding its market reach through online channels. He is currently focused on securing partnerships to expand market reach.

APYP OTC Market Information

The OTC Other tier represents the lowest tier of the OTC market, indicating that AppYea, Inc. may not meet the minimum financial or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, or may be undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and transparency compared to NYSE or NASDAQ-listed companies. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other securities.

  • OTC Tier: OTC Other
Liquidity: Liquidity in OTC markets, especially for OTC Other stocks like APYP, can be very limited. This often translates to low trading volumes and wide bid-ask spreads, making it difficult to buy or sell shares at desired prices. Investors may experience significant price slippage and difficulty exiting their positions, particularly with larger order sizes. The thin trading volume can also lead to increased price volatility and manipulation risks.
OTC Risk Factors:
  • Limited Liquidity: Low trading volume and wide bid-ask spreads can make it difficult to buy or sell shares.
  • Lack of Transparency: Limited financial reporting and regulatory oversight increase the risk of fraud and manipulation.
  • Financial Instability: Companies in the OTC Other tier may be financially distressed or have limited operating history.
  • Dilution Risk: Frequent stock dilutions can significantly reduce the value of existing shares.
  • Regulatory Scrutiny: OTC-listed companies are subject to less regulatory scrutiny than exchange-listed companies.
Due Diligence Checklist:
  • Verify the company's financial statements and SEC filings (if any).
  • Research the background and experience of the company's management team.
  • Assess the company's business model and competitive landscape.
  • Evaluate the company's capital structure and potential for dilution.
  • Review the company's legal and regulatory compliance.
  • Check for any red flags or warning signs in the company's history.
  • Understand the risks associated with investing in OTC-listed companies.
Legitimacy Signals:
  • Patents for sensor monitoring technology.
  • Development of SleepX and DreamIT product lines.
  • Focus on the growing market for digital health solutions.

APYP Technology Stock FAQ

What happened to AppYea, Inc. (APYP) stock?

AppYea, Inc. (APYP) no longer trades on public markets. The figures below are historical and are not a current quote.

Can I still buy APYP shares?

No. APYP stopped trading on public markets, so the shares are not available through a broker. Anything you see quoted for APYP elsewhere is historical data, not a live market.

Are the figures on this page current?

No. Every number here is the last value recorded before APYP stopped trading. Nothing on this page updates, and none of it is a current quote.

Why does this page still exist?

Because people still search for what happened to AppYea, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.

What does AppYea, Inc. do?

AppYea, Inc. is a digital health company that specializes in developing and marketing sensor-based monitoring and software solutions for individuals suffering from snoring and sleep apnea.

What do analysts say about APYP stock?

As of 2026-03-15, there is limited analyst coverage available for APYP stock due to its OTC listing and small market capitalization. Investors should conduct their own thorough research and due diligence before investing in APYP. Key valuation metrics to consider include the company's gross margin of 15.8% and its free cash flow of $-0.00B.

What are the main risks for APYP?

Investing in AppYea, Inc. carries several risks, including limited liquidity due to its OTC listing, competition from established medical device companies, and the potential for technological obsolescence. The company's small size and limited financial resources also present challenges.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Analysis updated

MoonshotScore is not published for this security.

Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data as of 2026-03-15.
  • OTC market data may be limited or unreliable.
  • Analyst coverage may be limited due to the company's size and OTC listing.
Data Sources
Financial Modeling Prep (FMP)Stock Expert AI proprietary analysis

More Stocks We Cover